Slide Insurance CRO sells 56,002 shares
Slide Insurance Holdings, Inc. Chief Risk Officer Matthew Paul Larson exercised stock options and sold the resulting shares in pre-planned transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Slide Insurance Holdings, Inc. Chief Risk Officer Matthew Paul Larson exercised stock options and sold the resulting shares in pre-planned transactions. On April 27, 2026 and April 29, 2026, he exercised options to acquire a total of 56,002 shares of common stock at an exercise price of $0.79 per share and sold the same 56,002 shares in open-market sales at weighted average prices of $18.77 and $20.02 per share.
The filing shows this exercise-and-sell pattern was carried out under a Rule 10b5-1 trading plan adopted on December 4, 2025, indicating the trades were pre-scheduled rather than timed discretionarily. After these transactions, the report shows no remaining common shares or related stock options from these grants held directly by Larson.
Insights
Pre-planned option exercise-and-sell by CRO, leaving no shares from these grants.
The Chief Risk Officer of Slide Insurance Holdings, Inc. exercised fully vested stock options at an exercise price of $0.79 per share and immediately sold all 56,002 resulting common shares in the open market at weighted average prices around $18.77 and $20.02.
The filing classifies this as an exercise-and-sell pattern, rather than an open-market purchase or simple sale of existing shares. A key detail is that the transactions were executed under a Rule 10b5-1 trading plan adopted on December 4, 2025, suggesting they were scheduled in advance and therefore carry less timing signal.
After these trades, the reported holdings show zero common shares and no remaining derivative position related to these options in this filing. Future company disclosures may provide broader context on the officer's overall equity exposure and any additional compensation awards beyond the grants exercised here.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 44,752 | $0.00 | $0.00 |
| Exercise | Common Stock | 44,752 | $0.79 | $35K |
| Sale | Common Stock | 44,752 | $20.02 | $896K |
| Exercise | Stock Option (Right to Buy) | 1,250 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,250 | $0.79 | $987.50 |
| Sale | Common Stock | 1,250 | $18.77 | $23K |
| Exercise | Common Stock | 10,000 | $0.79 | $8K |
| Sale | Common Stock | 10,000 | $18.77 | $188K |
Footnotes (4)
- F1. Exercised and sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.
- F2. Represents the weighted average price of the shares sold. The prices of the shares sold pursuant to the transactions ranges from $18.43 to $19.00 per share. The Reporting Person, upon request, will provide the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F3. Represents the weighted average price of the shares sold. The prices of the shares sold pursuant to the transactions ranges from $20.00 to $20.17 per share. The Reporting Person, upon request, will provide the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F4. These stock options are fully vested and exercisable.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
Stock Option (Right to Buy) financial
derivative security financial
fully vested and exercisable financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did SLDE’s Chief Risk Officer report in this Form 4?
Were the SLDE insider stock sales by Matthew Paul Larson pre-planned under a Rule 10b5-1 plan?
What stock options did the SLDE Chief Risk Officer exercise in these transactions?
Does the Slide Insurance Form 4 show remaining holdings for the Chief Risk Officer after these trades?
What is the significance of weighted average prices disclosed in the SLDE insider sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.